|
| Press Releases |
|
 |
|
| Thursday, April 24, 2025 |
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. more info >> |
|
|
君圣泰医药三项创新研究成果即将亮相2025欧肝会(EASL) |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法以解决代谢性疾病未满足临床需求的医药公司，今日宣布将于欧洲肝脏研究协会（EASL）2025年大会（5月7日-10日，荷兰阿姆斯特丹）上发表三项研究成果，分别为熊去氧胆小檗碱（HTD1801，一种全球首创的靶向肠-肝系统的抗炎及代谢调节剂）针对代谢相关脂肪性肝炎（MASH）治疗的临床2期研究事后分析结果、针对2型糖尿病（T2DM）治疗的临床2期研究事后分析结果，以及Rimtoregtide（HTD4010，一种Reg3α衍生肽）在肝衰竭小鼠中的临床前研究结果。 more info >> |
|
| Tuesday, April 15, 2025 |
|
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA |
| HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. more info >> |
|
|
熊去氧膽小檗堿（HTD1801）一藥多效 即將進入商業化新紀元 |
| 君聖泰醫藥（股票代碼: 2511.HK），一家專注于開發多功能創新療法以解決慢性肝病和代謝性疾病未滿足臨床需求的醫藥公司，今日宣佈，熊去氧膽小檗堿（HTD1801）在中國2型糖尿病（T2DM）患者中開展的兩項3期臨床試驗（SYMPHONY 1和SYMPHONY 2）達到主要療效終點及多個次要療效終點。 more info >> |
|
|
熊去氧胆小檗碱（HTD1801）一药多效 即将进入商业化新纪元 |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法以解决慢性肝病和代谢性疾病未满足临床需求的医药公司，今日宣布，熊去氧胆小檗碱（HTD1801）在中国2型糖尿病（T2DM）患者中开展的两项3期临床试验（SYMPHONY 1和SYMPHONY 2）达到主要疗效终点及多个次要疗效终点。 more info >> |
|
| Thursday, March 20, 2025 |
|
|
MASH疾病領域的大市場、大需求 |
| 代謝相關脂肪性肝炎（MASH）已成為全球醫藥行業正在挖掘的潛力「富礦」——2030年MASH市場規模將突破322億美元，患者人數超4.8億，至今FDA僅批准了一款藥物。MASH作為一種與代謝紊亂相關的肝臟疾病，表現為肝臟中脂肪異常堆積，並伴隨炎症和肝臟纖維化，可進展為肝硬化和肝細胞癌，是全球肝移植的主要病因，更顯著增加了心血管疾病的風險。 more info >> |
|
| Wednesday, March 19, 2025 |
|
|
MASH疾病领域的大市场、大需求 |
| 代谢相关脂肪性肝炎（MASH）已成为全球医药行业正在挖掘的潜力“富矿”——2030年MASH市场规模将突破322亿美元，患者人数超4.8亿，至今FDA仅批准了一款药物。 more info >> |
|
| Tuesday, March 4, 2025 |
|
|
重磅發佈 - 君聖泰醫藥在JAMA Network Open發表熊去氧膽小檗鹼治療2型糖尿病的臨床2期研究數據 療效顯著 多重代謝獲益 市場前景廣闊 |
| 中國深圳、美國馬里蘭州羅克維爾，君聖泰醫藥（股票代碼: 2511.HK），一家專注于開發多功能多靶點創新療法、解決代謝性疾病及慢性肝病未滿足臨床需求的醫藥公司，今日宣佈，熊去氧膽小檗堿（HTD1801）治療2型糖尿病（T2DM）的臨床2期研究結果在期刊JAMA Network Open發表。 more info >> |
|
|
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. more info >> |
|
|
重磅发布 - 君圣泰医药在JAMA Network Open发表熊去氧胆小檗碱治疗2型糖尿病的临床2期研究数据 疗效显著 多重代谢获益 市场前景广阔 |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能多靶点创新疗法、解决代谢性疾病及慢性肝病未满足临床需求的医药公司，今日宣布，熊去氧胆小檗碱（HTD1801）治疗2型糖尿病（T2DM）的临床2期研究结果在期刊JAMA Network Open发表。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase
Jun 19, 2025 9:30 JST
|
|
|
U.S. Polo Assn. 於佛羅倫斯聖母瑪利亞新教堂盛大慶祝品牌創立 135 週年，並在 Pitti Uomo 108 發表 2026 年春夏系列
Jun 19, 2025 07:00 HKT/SGT
|
|
|
容器如何加速人工智慧開發專案
Jun 19, 2025 07:00 HKT/SGT
|
|
|
Euro Manganese and Integrals Power Sign LOI and Offtake Term Sheet to Strengthen LMFP Battery Supply Chain
Jun 19, 2025 06:59 HKT/SGT
|
|
|
New method to blend functions for soft electronics
Jun 19, 2025 02:22: JST
|
|
|
HKTDC Maintains 3% Export Growth Forecast
Jun 18, 2025 23:06 HKT/SGT
|
|
|
"J-Style Trip Season 3" Tops Ratings for Twelve Consecutive Episodes
Jun 18, 2025 22:21 HKT/SGT
|
|
|
Data Turing Launches to Automate Brand Reputation Using Verifiable Truth
Jun 18, 2025 22:00: JST
|
|
|
Data Turing Launches to Automate Brand Reputation Using Verifiable Truth
Jun 18, 2025 22:00 HKT/SGT
|
|
|
New method to blend functions for soft electronics
Jun 18, 2025 20:00 HKT/SGT
|
|
|
Canstar Strengthens Technical Advisory Board with the Appointment of Geologist and VMS Mineralization Expert, Dr. Stephen J. Piercey, P.Geo., FGC
Jun 18, 2025 19:09 HKT/SGT
|
|
|
CleverTap Launches 'Promos' - The Industry-First All-In-One Rewards Management Platform
Jun 18, 2025 20:00 JST
|
|
|
《周遊記3》斬獲收視十二連冠！巨星傳奇IP生態與商業價值雙贏
Jun 18, 2025 16:30 HKT/SGT
|
|
|
《周游记3》斩获收视十二连冠！巨星传奇IP生态与商业价值双赢
Jun 18, 2025 16:30 HKT/SGT
|
|
|
のぞみエナジー、太陽光プロジェクト10件を買収し、ポートフォリオを約900MWに拡大
Jun 18, 2025 16:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
